

SUPPLEMENTAL MATERIAL

Table S1. Statins used in the non-high-intensity statin group.

	All patients who reviewed (n=4135)	Patients who achieved LDL-C target (n=1746)
Non-high-intensity statins*	(n=3517)	(n=1374)
Moderate-intensity statins	3377 (96.0)	1359 (98.9)
Atorvastatin 10mg	1480 (42.1)	562 (40.9)
Rosuvastatin 10mg	754 (21.4)	386 (28.1)
Atorvastatin 20mg	446 (12.7)	219 (15.9)
Simvastatin 20mg	386 (11.0)	91 (6.6)
Pitavastatin 2mg	109 (3.1)	36 (2.6)
Fluvastatin XL 80mg	90 (2.6)	33 (2.4)
Simvastatin 40mg	63 (1.8)	19 (1.4)
Pravastatin 40mg	49 (1.4)	13 (0.9)
Low-intensity statins	140 (4.0)	15 (1.1)
Pravastatin 10mg	120 (3.4)	12 (0.9)
Lovastatin 20mg	13 (0.4)	3 (0.2)
Pravastatin 20mg	7 (0.2)	-

Values are n (%).

* Definition of statin intensity was based on the guideline from 2013 ACC/AHA guideline on the treatment of blood cholesterol.

LDL-C = low-density lipoprotein cholesterol

Table S2. The number of patients under follow-up and without statin information.

Year of follow-up*		Total population		Propensity-matched population	
		High-intensity statin (n=372)	Non-high-intensity statin (n=1374)	High-intensity statin (n=367)	Non-high-intensity statin (n=798)
1 year	Patients under follow-up	343	1331	338	765
	Lack in information on statin type and dose	40	198	40	116
	Denominator in Table 3	303	1133	298	649
2 years	Patients under follow-up	241	1140	237	626
	Lack in information on statin type and dose	47	264	47	140
	Denominator in Table 3	194	876	190	486
3 years	Patients under follow-up	189	961	186	495
	Lack in information on statin type and dose	47	307	47	162
	Denominator in Table 3	142	654	139	333

*The denominators of Table 3 were calculated by subtracting the number of patients without statin information from the patients under follow-up at each year.